SCHEMBL1887364

SCHEMBL1887364

CCCN1CCCC1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
KCNK3 O14649 1/20 0.48
NR1I2 O75469 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ACE P12821 6/20 0.42
REN P00797 3/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.42
F2 P00734 1/20 0.42
LTA4H P09960 1/20 0.42
MAPT P10636 1/20 0.42
PEPD P12955 1/20 0.42
ALOX15 P16050 1/20 0.42
PTGS1 P23219 1/20 0.42
HTR2A P28223 1/20 0.42
PTGS2 P35354 1/20 0.42
HRH1 P35367 1/20 0.42
THPO P40225 1/20 0.42
PMP22 Q01453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3145758 1.00 LMNA (0.48) LMNAKCNK3NR1I2SMN1; SMN2ACE
SCHEMBL1887361 1.00 LMNA (0.48) LMNAKCNK3NR1I2SMN1; SMN2ACE
Hydrochloric Acid SCHEMBL9155025 0.98 LMNA (0.47) LMNAKCNK3NR1I2SMN1; SMN2ACE
Hydrochloric Acid SCHEMBL9155039 0.98 LMNA (0.47) LMNAKCNK3NR1I2SMN1; SMN2ACE
SCHEMBL23551811 0.94 KCNK3 (0.54) LMNAKCNK3NR1I2SMN1; SMN2ACE
SCHEMBL28148146 0.94 KCNK3 (0.54) LMNAKCNK3NR1I2SMN1; SMN2ACE
SCHEMBL669604 0.94 KCNK3 (0.54) LMNAKCNK3NR1I2SMN1; SMN2ACE
SCHEMBL28152186 0.93 KCNK3 (0.52) LMNAKCNK3NR1I2SMN1; SMN2SLC6A1
SCHEMBL5226944 0.93 KCNK3 (0.52) LMNAKCNK3NR1I2SMN1; SMN2SLC6A1
Hydrochloric Acid SCHEMBL28151982 0.93 KCNK3 (0.52) LMNAKCNK3NR1I2SMN1; SMN2SLC6A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105566411-B Lincomycin biosynthesis intermediate product and preparation method and application thereof 中国科学院上海有机化学研究所 2020-11-13 CN claimed
US-20180251486-A1 LINCOMYCIN BIOSYNTHETIC INTERMEDIATES, METHOD FOR PREPARATION, AND USE THEREOF HUZHOU CENTER OF BIO-SYNTHETIC INNOVATION, SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) 2018-09-06 US claimed
CN-105566411-A Lincomycin biosynthesized intermediate product and preparation method and use thereof SHANGHAI INST ORGANIC CHEMISTRY CAS 2016-05-11 CN claimed
US-20100076015-A1 Aminopyridine Derivatives VANTIA LIMITED (GB) 2010-03-25 US claimed
WO-2009133348-A1 AMINOPYRIDINE DERIVATIVES VANTIA LIMITED (GB) 2009-11-05 WO claimed
US-5665371-A SIDE EFFECT REDUCTION HOERRMANN WILHELM (DE) 1997-09-09 US claimed
EP-0253785-B1 EFFICIENT STEREOCONSERVATIVE SYNTHESES OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THEREIN ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1992-11-11 EP claimed
CN-120081711-A Method for preparing liquid fertilizer from lincomycin and ivermectin waste liquid 宁夏泰胜生物科技有限公司 2025-06-03 CN disclosed
CN-117987496-A Fermentation method for reducing lincomycin B component 宁夏泰益欣生物科技股份有限公司 2024-05-07 CN disclosed
WO-2023225534-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS PROTOMER TECHNOLOGIES INC. (US) 2023-11-23 WO disclosed
EP-3155436-B1 ISOBARIC MASS LABELS ELECTROPHORETICS LTD (GB) 2023-08-30 EP disclosed
CN-116036076-A Application of lithium amino acid in preparation of medicine for treating manic mental diseases 安域生物科技(杭州)有限公司 2023-05-02 CN disclosed
CN-112251456-B Method for improving lincomycin yield through streptomyces lincolnensis regulation gene combination modification 安徽大学 2022-05-03 CN disclosed
US-7425566-B2 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2008-09-16 US disclosed
US-5468876-A Intermediates for the stereoconservative synthesis of 1-substituted (S)-and (R)-2-aminomethylpyrrolidines AKTIEBOLAGET ASTRA (SE) 1995-11-21 US disclosed
US-5300660-A Efficient stereoconservative synthesis of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates thereto ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1994-04-05 US disclosed
CN-1021044-C PREPARATION METHOD FOR ACIDOPHOBIC-METHYL PROPYL PROLINE INTERMEDIATE D-3-ACETYLSULFURIC-2-METHYL-PROPIONY-L-PROLINE SHANGHAI MEDICAL INDUSTRY INST (CN) 1993-06-02 CN disclosed
EP-0253785-B1 EFFICIENT STEREOCONSERVATIVE SYNTHESES OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THEREIN ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1992-11-11 EP disclosed
EP-0270596-A1 A STEREOCONSERVATIVE SYNTHESIS OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THERETO ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1988-06-15 EP disclosed
WO-1987007271-A1 A STEREOCONSERVATIVE SYNTHESIS OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THERETO Astra Läkemedel Aktiebolag (SE) 1987-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076015-A1 Aminopyridine Derivatives CHRM1, ARG1, ARG2 LMNA 3185/4885KCNK3 814/4885NR1I2 641/4885
US-20180251486-A1 LINCOMYCIN BIOSYNTHETIC INTERMEDIATES, METHOD FOR PREPARATION, AND USE THEREOF COASY, DHPS, DCXR LMNA 188/4885KCNK3 3920/4885NR1I2 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.